^
Association details:
| Biomarker: | HER-2 negative |
|---|---|
| Cancer: | Gastroesophageal Junction Adenocarcinoma |
| Drug: | AiRuiKa (camrelizumab) (PD1 inhibitor) + AiTan (rivoceranib) (VEGFR-2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Space-neo study: a single arm study of apatinib combined with carrelizumab and SOX regimen in neoadjuvant treatment of local advanced gastric/gastroesophageal junction adenocarcinoma
Excerpt:
...1.Subjects aged 18 to 75 years (including 18 years old and 75 years old); 2.Understand the research procedures and content, and voluntarily sign a written informed consent form; 3.Adenocarcinoma of the stomach or gastroesophageal junction with HER2-negative or unknown HER2 status confirmed by histopathology and/or cytology. ...
Trial ID:
Source:
Title:
Camrelizumab Combined With Apatinib for Advanced Gastric or Esophagogastric Adenocarcinoma
Excerpt:
...It can provide the detection report of human epidermal growth factor receptor 2 (HER2); HER2 negative patients could be included in the study; HER2 positive patients who had failed to receive trastuzumab treatment in the past could be included in the study (HER2 positive was defined as ≥ 10% of tumor cells HER2 IHC 3 + or fish positive)； 6....
Trial ID:
More C2 evidence
Source:
Title:
Apatinib Plus Camrelizumab Combined With Docetaxel and S1 in First-line Treatment for Metastatic Gastric Cancer
Excerpt:
...Human epidermal growth factor receptor 2 (HER2) negative: immunohistochemical (IHC)...
Trial ID:
Source:
Title:
Single-arm, dose escalation and expansion study of low-dose Apatinib combined with Carrelizumab and SOX regimen in first-line treatment of advanced gastric/gastroesophageal junction adenocarcinoma
Excerpt:
...The clinical stage of gastric or gastroesophageal junction adenocarcinoma with HER2 negative or unknown HER2 status confirmed by histopathology and / or cytology is stage IV, which includes the tumor with clinical judgment of metastatic gastric cancer (cM1) and tumor invading adjacent organs (cT4b). ...
Trial ID:
Less C2 evidence
Source:
Title:
Camrelizumab plus low-dose apatinib and SOX in the first-line treatment of advanced gastric/gastroesophageal junction (G/GEJ) adenocarcinoma: A single-arm, dose escalation and expansion study (SPACE study).
Published date:
01/17/2023
Excerpt:
Patients (pts) aged 18-75 years, with unresectable or potentially resectable G/GEJ adenocarcinoma, HER2-negative...The ORR was 90.9%, with 30 (90.9%) PR. SD were 1 (3.0%) with a DCR of 93.9%. In addition, 9 pts showed an unconfirmed PR with a confirmed ORR of 80.8%. Median PFS was 10.2 months (95% CI, 5.5-22.3)...Camrelizumab plus apatinib and SOX followed by camrelizumab plus apatinib demonstrated encouraging antitumor activity and manageable toxicity as first line therapy for patients with G/GEJ adenocarcinoma.
Secondary therapy:
SOX
DOI:
10.1200/JCO.2023.41.3_suppl.365
Source:
Title:
Camrelizumab combined with chemotherapy followed by camrelizumab plus apatinib as first-line therapy for advanced gastric or gastroesophageal junction adenocarcinoma
Published date:
03/25/2021
Excerpt:
Systemic treatment naïve patients with human epidermal growth factor receptor 2-negative advanced or metastatic G/GEJ adenocarcinoma...were administrated subsequent camrelizumab plus apatinib....The ORR was 58.3% (95% CI, 43.2-72.4) with this combination regimen. Median duration of response was 5.7 months (95% CI, 4.4-8.3). Median overall survival was 14.9 months (95% CI, 13.0-18.6), and median progression-free survival was 6.8 months (95% CI, 5.6-9.5), respectively...
DOI:
10.1158/1078-0432.CCR-20-4691
Trial ID:
